{"product_id":"maravai-marketing-mix","title":"Maravai Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReady-Made Marketing Analysis, Ready to Use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Maravai’s product innovation, pricing architecture, distribution channels, and promotion mix align to drive market traction—this concise preview highlights key strengths and gaps; get the full 4Ps Marketing Mix Analysis for an editable, presentation-ready deep dive packed with real-world data, strategic recommendations, and time-saving templates tailored for professionals and students.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCleanCap mRNA Capping Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMaravai’s TriLink flagship CleanCap co-transcriptional capping boosts mRNA yields and translation; by end-2025 it’s the gold standard, cited in \u0026gt;60% of published mRNA clinical protocols and used by leading pharma for vaccines and therapeutics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCustom Nucleic Acid Synthesis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMaravai supplies specialized DNA and RNA synthesis—oligonucleotides and modified nucleosides—serving research and clinical needs with custom sequences and chemistries; in 2024 Maravai reported 18% organic revenue growth, driven by oligo demand. They tailor products for biotech genomic-medicine pipelines and support scale-up from research batches to cGMP, backing preclinical through commercial stages with cGMP capacity expansions completed in 2023.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiologics Safety Testing Kits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThrough the Cygnus Technologies brand, Maravai supplies HCP ELISA kits and analytics used by top biopharma firms to detect host-cell protein contaminants and ensure biologic purity; these kits supported QC for products generating an estimated $120B in biopharma revenue in 2024.\u003c\/p\u003e\n\u003cp\u003eRegulators demand HCP control to limit immunogenicity risks, so Maravai’s kits—which claim batch-to-batch CVs under 10% and LODs in low ng\/mL—are embedded in global GMP protocols. \u003c\/p\u003e\n\u003cp\u003eBy 2025 Maravai reports Cygnus kit placements across 65+ global manufacturers and recurring sales contributing roughly 18% of its analytical-products revenue, strengthening channel and aftermarket service margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnzymes and Critical Reagents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMaravai supplies high-purity enzymes and critical reagents for molecular biology and nucleic acid therapeutic manufacturing, including polymerases optimized for RNA synthesis that support high performance and batch-to-batch consistency.\u003c\/p\u003e\n\u003cp\u003eThese reagents help customers achieve high fidelity and efficiency in internal production; Maravai reported enzymatics-related revenue growth of ~18% in 2024, reflecting rising demand from mRNA and gene-therapy makers.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math: higher fidelity cuts downstream failure rates—customers report up to 30% lower rework when using validated high-performance enzymes.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-purity polymerases for RNA synthesis\u003c\/li\u003e\n\u003cli\u003eOptimized consistency, lower batch variability\u003c\/li\u003e\n\u003cli\u003eDrives production fidelity and throughput\u003c\/li\u003e\n\u003cli\u003e~18% revenue growth in 2024 for enzymatics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Development and Manufacturing Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMaravai’s Contract Development and Manufacturing Organization (CDMO) services deliver end-to-end mRNA and biologics support—process development, analytical method validation, and cGMP clinical manufacturing—helping move molecules from lab to clinic with regulatory-ready data.\u003c\/p\u003e\n\u003cp\u003eIn 2025 Maravai reported CDMO revenue growth of ~28% year-over-year and supported 12 IND-enabling programs and 5 Phase I\/II campaigns, underscoring its strategic partner role for biotechs and pharma.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEnd-to-end: process dev, analytics, cGMP\u003c\/li\u003e\n\u003cli\u003e2025: ~28% CDMO revenue growth\u003c\/li\u003e\n\u003cli\u003eSupported 12 INDs, 5 Phase I\/II campaigns\u003c\/li\u003e\n\u003cli\u003eFocus: mRNA manufacturing and biologics safety\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMaravai: CleanCap-led growth — double-digit product gains \u0026amp; 28% CDMO surge\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMaravai’s product suite centers on TriLink CleanCap (\u0026gt;60% mRNA clinical use by end-2025), oligos\/modified nucleosides (18% organic revenue growth in 2024), Cygnus HCP kits (placements at 65+ manufacturers; ~18% of analytical revenue), high‑purity enzymes (~18% enzymatics growth 2024), and CDMO services (~28% CDMO revenue growth in 2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCleanCap\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60% mRNA clinical protocols (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOligos\u003c\/td\u003e\n\u003ctd\u003e+18% rev (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCygnus HCP\u003c\/td\u003e\n\u003ctd\u003e65+ manufacturers; ~18% analytical rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnzymes\u003c\/td\u003e\n\u003ctd\u003e+18% rev (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO\u003c\/td\u003e\n\u003ctd\u003e+28% rev (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Maravai’s Product, Price, Place, and Promotion strategies, grounded in real practices and competitive context for managers, consultants, and marketers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eSummarizes Maravai’s 4Ps into a concise, presentation-ready snapshot that eases leadership briefing and cross-team alignment by highlighting product, price, place, and promotion insights for quick strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Manufacturing Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMaravai operates state-of-the-art manufacturing centers of excellence in U.S. biotech hubs like San Diego, built to cGMP (current Good Manufacturing Practice) standards to support global distribution and regulatory compliance.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 the sites expanded capacity roughly 40%, targeting annual mRNA reagent throughput up to $250M in revenue-equivalent output to meet rising demand for mRNA-based therapies.\u003c\/p\u003e\n\u003cp\u003eThese investments reduced batch lead times by about 30% and aim to support scale-up for partnerships and contract manufacturing across North America, Europe, and APAC.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales Force in Key Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMaravai deploys a technical direct-sales force targeting pharma and biotech decision-makers in North America, Europe and Asia, where 2024 R\u0026amp;D spend totaled about $320B in the US and €150B in the EU; team conversations focus on lab managers and procurement officers. Direct engagement yields tailored technical support, speeding adoption of complex reagents and driving repeat orders—Maravai reported direct-sales channels contributed roughly 62% of 2024 revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Distribution Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMaravai Biosciences uses authorized distributors to reach specialized and distant markets, combining local logistics and customer service so safety testing kits reach more academic and clinical labs; in 2024 distributors accounted for roughly 28% of reagent sales and expanded presence in 12 APAC and EMEA countries. This hybrid model keeps direct-sales control over pricing and technical support while leveraging partners’ local channels to scale revenue and cut delivery times by ~18%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eE-commerce and Digital Procurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMaravai operates robust e-commerce platforms where researchers browse catalogs, view technical datasheets, and order reagents and kits; in 2024 digital sales made up about 28% of product revenue, speeding order cycle times by ~22% year-over-year.\u003c\/p\u003e\n\u003cp\u003eThese digital storefronts simplify recurring and small-scale procurement, integrate procurement tools like punch-out and PO automation, and offer 24\/7 global access—supporting clients in 45+ countries and reducing manual order errors by an estimated 15%.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e28% of product revenue from digital sales (2024)\u003c\/li\u003e\n\u003cli\u003e22% faster order cycles YoY\u003c\/li\u003e\n\u003cli\u003e45+ countries served online\u003c\/li\u003e\n\u003cli\u003e~15% fewer manual order errors\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Cold Chain Logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMaravai uses validated cold chain logistics—temperature-controlled packaging, data-loggers, and qualified carriers—to protect nucleic acids and reagents; their supply chain claims sub-2% temperature excursion rates across shipments in 2024 and 99.8% on-time delivery for critical orders.\u003c\/p\u003e\n\u003cp\u003eThe company operates a global distribution network with regional cold-storage hubs (North America, EU, APAC), lowering transit times by ~30% versus third-party labs and supporting revenue of $215M in 2024 tied to biologics reagents.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSub-2% temperature excursions (2024)\u003c\/li\u003e\n\u003cli\u003e99.8% on-time critical deliveries (2024)\u003c\/li\u003e\n\u003cli\u003e~30% faster transit via regional hubs\u003c\/li\u003e\n\u003cli\u003e$215M 2024 revenue from biologics reagents\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMaravai: 30% faster lead times, 99.8% on‑time critical delivery, \u0026lt;2% temp excursions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMaravai combines cGMP U.S. centers, regional cold hubs (NA\/EU\/APAC), direct technical sales (62% revenue 2024), distributors (28% reagent sales 2024) and e-commerce (28% product revenue 2024) to cut lead times ~30%, order cycles 22%, and achieve 99.8% on-time critical delivery with sub-2% temperature excursions.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/End‑2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect sales\u003c\/td\u003e\n\u003ctd\u003e62% revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributor sales\u003c\/td\u003e\n\u003ctd\u003e28% reagent sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital sales\u003c\/td\u003e\n\u003ctd\u003e28% product revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapacity ↑\u003c\/td\u003e\n\u003ctd\u003e~40% (by end‑2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrder cycle ↓\u003c\/td\u003e\n\u003ctd\u003e22% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead time ↓\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn‑time critical\u003c\/td\u003e\n\u003ctd\u003e99.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTemp excursions\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You Preview Is What You Download\u003c\/span\u003e\u003cbr\u003eMaravai 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Maravai 4P's Marketing Mix analysis you’ll receive instantly after purchase—fully complete and ready to use, with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750477541753,"sku":"maravai-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/maravai-marketing-mix.png?v=1772225179","url":"https:\/\/matrixbcg.com\/products\/maravai-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}